ABC | Volume 111, Nº3, Setembro 2018

Artigo Original Radaelli et al Dislipidemia secundária em crianças obesas Arq Bras Cardiol. 2018; 111(3):356-361 1. Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, Williams K, Neely B, Sniderman AD, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370(15):1422-31. 2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38-360. Erratum in: Circulation. 2016;133(15):e599. 3. Kit BK, Kuklina E, Carrol MD, Ostchega Y, Freedman DS, Ogden CL. Prevalence of and trends in dyslipidemia and blood pressure among US children and adolescents, 1999-2012. JAMA Pediatr. 2015;169(3):272-9. 4. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes. 2006;1(1):11-25. 5. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213-56. 6. Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. J Pediatr Pharmacol Ther. 2010;15(3):160-72. 7. D’AdamoE,GuardamagnaO,ChiarelliF,BartuliA,LiccardoD,FerrariF,etal. Atherogenic dyslipidemia and cardiovascular risk factors in obese children. Int J Endocrinol. 2015;2015:912047. 8. Steinberger J, Moorehead C, Katch V, Rocchini AP. Relationship between insulin resistance and abnormal lipid profile in obese adolescents. J Pediatr. 1995;126(5 Pt 1):690-5. 9. Stan S, Levy E, Delvin EE, Hanley JA, Lamarche B, O’Loughlin J, et al. Distribution of LDL particle size in a population-based sample of children and adolescents and relationshipwith other cardiovascular risk factors. Clin Chem. 2005;51(7):1192-200. 10. BirchLL.Developmentof foodpreferences.AnnuRevNutr.1999;19:41-62. 11. Kelder SH, Perry CL, Klepp KI, Lytle LL. Longitudinal tracking of adolescent smoking, physical activity, and food choice behaviors. Am J Public Health. 1994;84(7):1121-6. 12. Hiddink GJ, Hautvast JG, van Woerkum CM, Fieren CJ, Van’t Hof MA. Nutrition guidance by primary-care physicians: perceived barriers and low involvement. Eur J Clin Nutr. 1995;49(11):842-51. 13. Levine BS, Wigren MM, Chapman DS, Kerner JF, Bergman RL, Rivlin RS. A national survey of attitudes and practices of primary-care physicians relating to nutrition: strategies for enhancing the use of clinical nutrition in medical practice. Am J Clin Nutr. 1993;57(2):115-9. 14. Krebs NF, Himes JH, JacobsonD, Nicklas TA, Guilday P, StyneD. Assessment of child and adolescent overweight and obesity. Pediatrics. 2007;120 Suppl 4:S193-228. 15. Kushner RF. Barriers to providing nutrition counseling by physicians: a survey of primary care practitioners. Prev Med. 1995;24(6):546-52. 16. Hiddink GJ, Hautvast JG, Van Woerkum CM, Fieren CJ, Van‘t Hof MA. Driving forces for and barriers to nutrition guidance practices of Dutch primary-care physicians. J Nutr Educ. 1997;29(1):36-41. 17. Braamskamp M, Wijburg FA, Wiegman A. Drug therapy of hypercholesterolaemia in children and adolescents. Drugs. 2012;72(6):759-72. 18. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, et al; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32):2146-57. 19. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D.What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol. 2008;19(4):362-8. 20. Li S, Chen W, Srinivasan SR, Xu J, Berenson GS. Relation of childhood obesity/cardiometabolic phenotypes to adult cardiometabolic profile: the Bogalusa Heart Study. Am J Epidemiol. 2012;176 Suppl 7:S142-9. 21. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37. 22. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Beauloye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272-80. 23. U.S. Food&Drug-Administration. Federal drug authority. [Accessed in 2016 July 27]. Available from: http://www.fda.gov . 24. O’Brien EC, Roe MT, Fraulo ES, Peterson ED, Ballantyne CM, Genest J, et al. Rationale and design of the familial hypercholesterolemia foundation cascade screening for awareness and detection of familial hypercholesterolemia registry. AmHeart J. 2014;167(3):342-9. 25. Belay B, Belamarich PF, Tom-Revzon C. The use of statins in pediatrics: knowledge base, limitations, and future directions. Pediatrics. 2007;119(2):370-80. 26. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. Erratum in: Lancet. 2005;366(9494):1358; Lancet. 2008;371(9630):2084. 27. Ose L, Budinski D, Hounslow N, Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210(1):202-8. Erratum in: Atherosclerosis. 2010;212(2):704. 28. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781-90. 29. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121-6. 30. Clauss SB, Holmes KW, Hopkins P, Stein E, ChoM, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116(3):682-8. 31. Braamskamp MJ, Stefanutti C, Langslet G, Drogari E, Wiegman A, HounslowN, et al; PASCAL Study Group. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. J Pediatr. 2015;167(2):338-43. 32. Lebenthal Y, Horvath A, Dziechciarz P, Szajewska H, Shamir R. Are treatment targets for hypercholesterolemia evidence based? Systematic review and meta-analysis of randomised controlled trials. Arch Dis Child. 2010:95(9):673-80. 33. O’Gorman CS, O’Neill M, Conwell L. Considering statins for cholesterol- reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2010 Dec 20;7:1-14. 34. Nupponen M, Pahkala K, Juonala M, Magnussen CG, Niinikoski H, Rönnemaa T, et al. Metabolic syndrome from adolescence to early adulthood: effect of infancy-onset dietary counseling of low-saturated-fat: the special turku coronary risk factor intervention project (strip). Circulation. 2015;131(7):605-13. Referências 360